Erik S. Miller became Vice President of Marketing and Business Development on January 17, 2011, after serving as a consultant since October 2010. He has over twenty years of experience in healthcare marketing, management, sales, and business development.
Most recently, Miller served as Vice President of Business Development and Marketing at Radix Biosolutions from April 2008 to March 2010, directing the launch of the company's first commercial products and services. Previously, he held positions of increasing marketing and business responsibility at Luminex Corporation (2005-2008), Safety Syringes, Inc., and Biosite Diagnostics.
Miller earned a Bachelor of Science in Pharmacy from the University of Iowa and an MBA from the University of North Carolina. He has co-authored three peer-reviewed scientific articles on growth factor cell signaling and drug delivery.
Biography extracted from Riot PRE 14A filed 2011-06-01 View cached copy (2026-09-27)Live source ↗
Roles
Contiguous filings for the same role are collapsed into a single tenure span. Click a row to see the underlying filings.
| Company | Role | Tenure | Filings |
|---|---|---|---|
| Riot | VP Marketing & Bus Development | 2011-01 → present (15y 10mo) | 2 |
Show 2 underlying filings | |||
Insider transactions
Totals for this person
| Bucket | Invested (shares) | Invested (USD) | Divested (shares) | Divested (USD) | Net direction | Txns | Invested @ last price | Divested @ last price |
|---|---|---|---|---|---|---|---|---|
| All time | 215,000 | $0 | - | $0 | Flat | 2 | $2.75M | $0 |
| 2012 | 15,000 | $0 | - | $0 | Flat | 1 | $192.2K | $0 |
| 2011 | 200,000 | $0 | - | $0 | Flat | 1 | $2.56M | $0 |
| 2011-Q1 | 200,000 | $0 | - | $0 | Flat | 1 | $2.56M | $0 |
| 2012-Q2 | 15,000 | $0 | - | $0 | Flat | 1 | $192.2K | $0 |
Invested = shares acquired (buys, grants, option exercises) — insider adding to the position. Divested = shares reduced (sells, dispositions, tax-withholding) — cash flowing TO the insider. Net direction shows which side wins on dollar terms in each bucket. % of holder's stake not yet computed (pending Form 3/4 holdings ingest). See methodology. The two @ last price columns restate the same share counts at the most recent share price we read (close of 2026-10-30); they are a valuation, not a cash flow, and they move every day the market does.
All transactions
| Date | Company | Kind | Shares | Amount (USD) | Value @ last price |
|---|---|---|---|---|---|
| 2012-04-30 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 15,000 | - | $192.2K |
| 2011-01-17 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 200,000 | - | $2.56M |